Mark Bachleda
Officer at Galera Therapeutics, Inc. (GRTX) since October 2021
Mark Bachleda has filed 7 insider reports with the SEC since October 2021, as director at Lyell Immunopharma, Inc. (LYEL) and officer at Galera Therapeutics, Inc. (GRTX). The latest filing, on June 12, 2026, reports grant or award at Lyell Immunopharma, Inc. (LYEL).
- Filings
- 7
- Companies
- 2
- Bought on market
- None
- Sold on market
- None
Companies where Mark Bachleda is an insider
| Company | Role | Shares held | Bought | Sold | Avg buy | Price now | Last filing |
|---|---|---|---|---|---|---|---|
| Directorsince June 2025 | $13.89 | Jun 12, 2026 | |||||
| Officersince October 2021 | Mar 1, 2023 |
Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.
Every filing
- Jun 10, 2026LYELSEC Form 4 filed by Director Bachleda MarkForm 4Grant or award
- Jun 9, 2025LYELSEC Form 4 filed by Director Bachleda MarkForm 4Grant or award
- Jun 9, 2025LYELMark Bachleda became an insiderForm 3New insider
- Feb 25, 2023GRTXSEC Form 4 filed by Bachleda MarkForm 4Grant or award
- Feb 28, 2022GRTXSEC Form 4 filed by Bachleda MarkForm 4Grant or award
- Oct 8, 2021GRTXSEC Form 4 filed by Bachleda MarkForm 4Grant or award
- Oct 8, 2021GRTXMark Bachleda became an insiderForm 3New insider
Compare Mark Bachleda with
- Mark Bachleda vs Gary K. Lee1 shared
- Mark Bachleda vs Stephen J. Hill1 shared
- Mark Bachleda vs Lynn Seely1 shared
- Mark Bachleda vs Veronica Sanchez Bulis1 shared
- Mark Bachleda vs David Shook1 shared
- Mark Bachleda vs Jarrad Mattieu Aguirre1 shared
Other insiders at the same companies
- Gary K. LeeLYEL
- Stephen J. HillLYEL
- Lynn SeelyLYEL
- Veronica Sanchez BulisLYEL
- ARCH Venture Partners IX, LLCLYEL
- ARCH Venture Fund XIII, L.P.LYEL
- David ShookLYEL
- Jarrad Mattieu AguirreLYEL
- Mel SorensenGRTX
- Kevin G LokayGRTX
- Nancy T ChangGRTX
- Lawrence M AllevaGRTX
- Joel F. SussmanGRTX
- Michael R. FriedmanGRTX
- Innovative Cellular Therapeutics Holdings LtdLYEL
- William Jl RieflinLYEL
Questions about Mark Bachleda
- What is Mark Bachleda's role at Galera Therapeutics, Inc.?
- Mark Bachleda reports to the SEC as officer at Galera Therapeutics, Inc. (GRTX), according to the latest filing on March 1, 2023. Mark Bachleda has also filed as director at Lyell Immunopharma, Inc. (LYEL).
- Has Mark Bachleda bought or sold stock recently?
- No open-market purchases or sales by Mark Bachleda are on file. The filings report grant or award.
- How do I get alerts when Mark Bachleda files?
- Follow Mark Bachleda on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.
From SEC Forms 3, 4, 5 and 144 filed by Mark Bachleda (SEC CIK 0001887762). Totals count each trade once, skipping amendments whose original is on file, from Oct 13, 2021 on. View on SEC EDGAR